Edinburgh‑based Trogenix closed a $95 million Series A to advance its Odysseus platform and push its lead glioblastoma programme toward a planned first‑in‑human entry in early 2026. Investors on the round included IQ Capital, 4BIO Capital, Eli Lilly, and patient‑focused funds such as the National Brain Tumor Society’s Brain Tumor Investment Fund. Trogenix’s approach uses synthetic super enhancers delivered by AAV to selectively activate therapeutic payloads inside cancer cells, combining prodrug activation with local cytokine release. Management says the funding will support IND‑enabling work and early clinical execution for aggressive solid tumors where current options are limited.